A Study to Establish the Safety and Tolerability of Zimura™ (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)

NCT02397954 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

4

Enrollment

INDUSTRY

Sponsor class

Conditions

Idiopathic Polypoidal Choroidal Vasculopathy

Interventions

DRUG: Avacincaptad Pegol

Sponsor

Ophthotech Corporation